Contribute Try STAT+ Today

As Americans debate whether to import prescription drugs from Canada to relieve rising costs, a new government report finds that 16% of medicines examined could not be traced back to their manufacturers, underscoring ongoing concerns about the security of the pharmaceutical supply chain.

Specifically, documentation was lacking or mismatched for six of 44 so-called high-risk prescription drugs, although in one instance, a wholesaler refused to provide paperwork, according to the report from the Office of Inspector General of the Department of Health and Human Services, which reviewed Medicare Part D claims that were billed between January and May 2018.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.